Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2018 Aug 9;17(11):2297–2308. doi: 10.1158/1535-7163.MCT-17-1239

Figure 6: Inhibition of AXL increases MERTK protein expression and co-inhibition of AXL and MERTK suppresses tumor growth in vivo.

Figure 6:

Subcutaneous xenografts were generated in nude mice using (A, D) the TNBC MDAMB231 cell line, (B) the HNSCC UW-SCC1 patient-derived xenograft (PDX), or (C) the HNSCC UM-SCC1 cell line. Tumor-bearing mice were treated with vehicle, 25mg/kg R428, 25 mg/kg UNC2025, or R428+UNC2025 administered twice daily via oral gavage. MERTK expression was assessed in tumor cell lysates by immunoblot. α-Tubulin was used as a loading control. (A) MERTK expression was also detected in MDAMB231 tumors using immunohistochemistry. (B, C, D) Tumor volume was measured (n=8 per group). (C, D) pS6rp and Ki67 were detected in tumor sections using IHC. Mean values and standard errors are shown. *p<0.05, **p<0.01, NS=not significant.